TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of Full-time Bangerter Filters Versus Part-time Daily Patching for the Treatment of Moderate Amblyopia in Children
Brief Summary: This study is a randomized clinical trial designed to evaluate the non-inferiority of Bangerter filters compared to 2 hours of daily patching as a primary treatment for moderate amblyopia (20/40 to 20/80) in children ages 3 to \< 10 years.

Secondary objectives of this study are (1) to determine the time course of visual improvement with Bangerter filter treatment, (2) to compare patient quality of life, measured by a modified Amblyopia Treatment Index, between patients treated with patching vs. Bangerter filters, (3) to determine whether blurring the sound eye to a visual acuity worse than the amblyopic eye predicts improvement in acuity, and (4) to determine whether a change in fixation to the amblyopic eye is predictive of improvement in visual acuity.

The primary outcome assessment is visual acuity at 24 weeks for both the amblyopic and sound eyes.

The primary analytic approach for the amblyopic eye acuity will involve construction of a one-sided 95% confidence interval to assess non-inferiority based on a treatment group comparison of logMAR visual acuity scores adjusted for baseline visual acuity scores in an analysis of covariance (ANCOVA) model.

Sound eye acuity data will be reported for each treatment regimen at the 24-week visit as mean change (logMAR lines) from baseline and as the distribution of the number of lines of change from baseline.


Options:
A: Arm Label: I-BiTTM game; Type: EXPERIMENTAL; Interventions: Device: I-BiTTM game | Arm Label: Non-I-BiTTM game; Type: ACTIVE_COMPARATOR; Interventions: Device: Non-I-BiTTM game | Arm Label: I-BiTTM DVD; Type: EXPERIMENTAL; Interventions: Device: I-BiTTM DVD | Intervention Type: DEVICE; Name: I-BiTTM game; Assigned to Arm(s): I-BiTTM game | Intervention Type: DEVICE; Name: Non-I-BiTTM game; Assigned to Arm(s): Non-I-BiTTM game | Intervention Type: DEVICE; Name: I-BiTTM DVD; Assigned to Arm(s): I-BiTTM DVD
B: Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Eye Patch; Assigned to Arm(s): Patching
C: Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Patching, Procedure: Near activities | Arm Label: Bangerter filters; Type: ACTIVE_COMPARATOR; Interventions: Device: Bangerter filters, Procedure: Near activities | Intervention Type: DEVICE; Name: Bangerter filters; Assigned to Arm(s): Bangerter filters | Intervention Type: DEVICE; Name: Patching; Assigned to Arm(s): Patching | Intervention Type: PROCEDURE; Name: Near activities; Assigned to Arm(s): Bangerter filters, Patching
D: Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maintaining Alcohol Abstinence in Alcoholic Patients With Liver Cirrhosis: Efficacy and Safety of Baclofen Administration in a Randomized Double Blind Controlled Study
Brief Summary: Intervention to achieve alcohol abstinence represents the most effective treatment for alcoholic patients with liver cirrhosis. However no trials have evaluated the efficacy of anti-craving drugs in these patients because of the concern that these medications might worsen liver disease. Baclofen is effective to reduce alcohol craving improving abstinence in alcohol-dependent patients. It is mainly eliminated by kidney. No hepatic side-effects have been reported in treated patients. The present study investigates the efficacy and safety of baclofen in achieving and maintaining abstinence in alcoholic cirrhotic patients.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Baclofen 30mg/day | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Baclofen 75mg/day | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Baclofen 30mg/day; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Baclofen 75mg/day; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 3
B: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Baclofen | Intervention Type: DRUG; Name: Baclofen; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: BACLOFEN; Type: EXPERIMENTAL; Interventions: Drug: BACLOFEN | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: PLACEBO | Intervention Type: DRUG; Name: BACLOFEN; Assigned to Arm(s): BACLOFEN | Intervention Type: DRUG; Name: PLACEBO; Assigned to Arm(s): PLACEBO
D: Arm Label: ITB therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: intrathecal baclofen | Arm Label: Best Medical Treatment (BMT); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: intrathecal baclofen; Assigned to Arm(s): ITB therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maintaining Alcohol Abstinence in Alcoholic Patients With Liver Cirrhosis: Efficacy and Safety of Baclofen Administration in a Randomized Double Blind Controlled Study
Brief Summary: Intervention to achieve alcohol abstinence represents the most effective treatment for alcoholic patients with liver cirrhosis. However no trials have evaluated the efficacy of anti-craving drugs in these patients because of the concern that these medications might worsen liver disease. Baclofen is effective to reduce alcohol craving improving abstinence in alcohol-dependent patients. It is mainly eliminated by kidney. No hepatic side-effects have been reported in treated patients. The present study investigates the efficacy and safety of baclofen in achieving and maintaining abstinence in alcoholic cirrhotic patients.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Baclofen 30mg/day | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Baclofen 75mg/day | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Baclofen 30mg/day; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Baclofen 75mg/day; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 3
B: Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Benfotiamine; Type: EXPERIMENTAL; Interventions: Drug: Benfotiamine | Intervention Type: DRUG; Name: Benfotiamine; Assigned to Arm(s): Benfotiamine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control Group
C: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Baclofen | Intervention Type: DRUG; Name: Baclofen; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: Baclofen; Type: EXPERIMENTAL; Interventions: Drug: Baclofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Baclofen; Assigned to Arm(s): Baclofen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extended Release Nifedipine Treatment as Maintenance Tocolysis to Prevent Preterm Delivery:A Prospective Interventional Study
Brief Summary: To evaluate the treatment efficacy and safety usig extended release nifedipine, as maintenance therapy to pregnant women who were hospitalized and treated for preterm labor until 34 weeks' gestation. After the PTL will stop, we will randomize these women for the treatment group and the control (no treatment) group.

The main outcome will be preterm delivery before 34 weeks' gestation. the secondary outcome will be the side effects of the medication and the newborn/mother health variables.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Nifedipine extended release | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Nifedipine extended release; Assigned to Arm(s): A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium sulfate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral Nifedipine or placebo | Intervention Type: DRUG; Name: Magnesium sulfate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Oral Nifedipine or placebo; Assigned to Arm(s): 2
C: Arm Label: group Nicorandil; Type: OTHER; Interventions: Drug: Potassium Channel Opener | Arm Label: group Nifedipine; Type: OTHER; Interventions: Drug: Calcium channel blocker | Intervention Type: DRUG; Name: Potassium Channel Opener; Assigned to Arm(s): group Nicorandil | Intervention Type: DRUG; Name: Calcium channel blocker; Assigned to Arm(s): group Nifedipine
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nifedlipine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium | Intervention Type: DRUG; Name: Magnesium; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Nifedlipine; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled Two-year Trial to Examine the Changes in Exercise Endurance and COPD Treated With Tiotropium Once Daily (EXACTT)
Brief Summary: The objective of this study is to evaluate the effects on exercise duration of 96 weeks treatment with 18 mcg tiotropium (Spiriva HandiHaler) daily as compared to placebo, in patients with COPD.


Options:
A: Arm Label: tiotropium 18mcg; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 18 mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: tiotropium 18 mcg; Assigned to Arm(s): tiotropium 18mcg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): N/A
D: Arm Label: Tiotropium; Type: OTHER; Interventions: Drug: Tiotropium | Arm Label: Placebo; Type: OTHER; Interventions: Device: Respimat | Intervention Type: DEVICE; Name: Respimat; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Phase II Feasibility Study Investigating the Biological Effects of the Addition of Zoledronic Acid to Neoadjuvant Combination Chemotherapy on Invasive Breast Cancer
Brief Summary: There is clear preclinical in vitro and in vivo evidence of sequence dependent synergy between chemotherapy agents and zoledronic acid. The aim of the study is to investigate if the synergistic increase in tumour cell apoptosis observed in preclinical studies occurs in patients. The hypothesis for this study is that there may be anti-tumour benefits of the sequential application of chemotherapy agents followed by zoledronic acid in patients with invasive breast cancer.


Options:
A: Arm Label: Zometa; Type: EXPERIMENTAL; Interventions: Drug: Zometa, Drug: Epirubicin, Drug: Docetaxel, Drug: Trastuzumab, Radiation: External beam radiation, Procedure: Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection | Arm Label: No Zometa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epirubicin, Drug: Docetaxel, Drug: Trastuzumab, Radiation: External beam radiation, Procedure: Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection | Intervention Type: DRUG; Name: Zometa; Assigned to Arm(s): Zometa | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): No Zometa, Zometa | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): No Zometa, Zometa | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): No Zometa, Zometa | Intervention Type: RADIATION; Name: External beam radiation; Assigned to Arm(s): No Zometa, Zometa | Intervention Type: PROCEDURE; Name: Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection; Assigned to Arm(s): No Zometa, Zometa
B: Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A
C: Arm Label: Pamidronate and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pamidronate, Drug: placebo | Arm Label: Zoledronic acid and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zoledronic acid, Drug: placebo | Intervention Type: DRUG; Name: Pamidronate; Assigned to Arm(s): Pamidronate and placebo | Intervention Type: DRUG; Name: Zoledronic acid; Assigned to Arm(s): Zoledronic acid and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Pamidronate and placebo, Zoledronic acid and placebo
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid | Intervention Type: DRUG; Name: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Open-label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to Compare the Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe and Simvastatin in Patients With Hypercholesterolaemia and CHD
Brief Summary: The purpose of this study is to determine whether treatment of Rosuvastatin (CRESTOR™) or Simvastatin given as monotherapy or given in combination with Ezetimibe, will lower the Low Density Lipoprotein Cholesterol (LDL-C) in patients with Hypercholesterolaemia and Coronary Heart Disease (CHD) or a CHD Risk Equivalent, Atherosclerosis or a 10-year CHD Risk of \>20%


Options:
A: Intervention Type: DRUG; Name: MK0653A, ezetimibe (+) simvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: Rosuvastatin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Rosuvastatin (Crestor); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: rosuvastatin calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study
Brief Summary: To evaluate the safety, tolerability and efficacy of 3 doses of vernakalant (oral) (150 mg, 300 mg and 500 mg b.i.d.) administered for up to 90 days in subjects with sustained symptomatic atrial fibrillation (AF duration \> 72 hours and \< 6 months).


Options:
A: Arm Label: AF ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Atrial Fibrillation ablation | Arm Label: Amiodarone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amiodarone | Intervention Type: PROCEDURE; Name: Atrial Fibrillation ablation; Assigned to Arm(s): AF ablation | Intervention Type: DRUG; Name: Amiodarone; Assigned to Arm(s): Amiodarone
B: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: dronedarone (SR33589) | Arm Label: Amiodarone 600mg/200mg od; Type: ACTIVE_COMPARATOR; Interventions: Drug: amiodarone | Intervention Type: DRUG; Name: dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: amiodarone; Assigned to Arm(s): Amiodarone 600mg/200mg od
C: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: Dronedarone (SR33589) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vernakalant (oral) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Vernakalant (oral) | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Vernakalant (oral) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vernakalant (oral); Assigned to Arm(s): 2, 3, 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Recurrent Abdominal Pain in Children
Brief Summary: The purpose of this study is to:

1. To determine if fiber versus placebo improves symptoms in children with recurrent abdominal pain/irritable bowel syndrome.
2. To determine possible ways fiber or placebo improve(s) symptoms in children with recurrent abdominal pain/irritable bowel syndrome by carrying out gastrointestinal tests and questionnaires.

Understanding how diet and fiber affect GI function potentially will benefit the large numbers of children with irritable bowel syndrome (IBS) and provide insight into prevention of IBS in at risk children. We expect that the results from these studies can be used to lessen significantly the huge financial burden to society caused by these chronic conditions.

Consent will be obtained from the parent/guardian and assent from the child.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Probiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lactobacillus GG (probiotic ) | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus GG (probiotic ); Assigned to Arm(s): Probiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Fiber; Type: EXPERIMENTAL; Interventions: Behavioral: Elimination Diet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Elimination Diet | Intervention Type: BEHAVIORAL; Name: Elimination Diet; Assigned to Arm(s): Fiber, Placebo
C: Arm Label: Probiotics supplementation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Glucomannan; Type: EXPERIMENTAL; Interventions: Drug: Glucomannan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Glucomannan; Assigned to Arm(s): Glucomannan | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of Routine Screening for Intimate Partner Violence
Brief Summary: This is a randomized controlled trial with three arms to establish the impact of screening and referral to services for women disclosing exposure to IPV.


Options:
A: Arm Label: Screened; Type: EXPERIMENTAL; Interventions: Other: screened | Arm Label: Universal education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: universal education | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: screened; Assigned to Arm(s): Screened | Intervention Type: BEHAVIORAL; Name: universal education; Assigned to Arm(s): Universal education
B: Arm Label: Model Care (SEEK); Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced pediatric primary care | Arm Label: Standard pediatric primary care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard pediatric primary care | Intervention Type: BEHAVIORAL; Name: Enhanced pediatric primary care; Assigned to Arm(s): Model Care (SEEK) | Intervention Type: BEHAVIORAL; Name: Standard pediatric primary care; Assigned to Arm(s): Standard pediatric primary care
C: Intervention Type: DEVICE; Name: Interactive computer based health-risk survey before doctor's visit; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Stepping Stones | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: stepping Stones short | Intervention Type: BEHAVIORAL; Name: Stepping Stones; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: stepping Stones short; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to evaluate the impact of a a real time teleassistance system in the clinical evolution of type 2 diabetic patients on self monitoring blood glucose in the Public National Primary Care System.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemedicine group; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine system | Intervention Type: DEVICE; Name: Telemedicine system; Assigned to Arm(s): Telemedicine group
B: Arm Label: Control-usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention paired testing and remote monitoring; Type: EXPERIMENTAL; Interventions: Behavioral: Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose | Intervention Type: BEHAVIORAL; Name: Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose; Assigned to Arm(s): Intervention paired testing and remote monitoring
C: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive care | Arm Label: Intensive Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive care | Intervention Type: OTHER; Name: Intensive care; Assigned to Arm(s): Intensive Care, Usual Care
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Technology Assisted Case Management; Type: EXPERIMENTAL; Interventions: Behavioral: Technology-Assisted Case Management | Intervention Type: BEHAVIORAL; Name: Technology-Assisted Case Management; Assigned to Arm(s): Technology Assisted Case Management

Answer: A